This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7-30.SiegelRLMillerKDJemalA. Cancer statistics, 2020. 2020; 70(1): 7-30.Search in Google Scholar
Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8): 1623-1640.DumaNSantana-DavilaRMolinaJR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. 2019; 94(8): 1623-1640.Search in Google Scholar
Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, et al. EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res. 2016; 8(11-20.VázquezSCasalJAfonso AfonsoFJFírvidaJLSantoméLBarónFEGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). 2016; 8:11-20.Search in Google Scholar
Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021; 22(5):.RebuzziSEZulloLRossiGGrassiMMurianniVTagliamentoMNovel Emerging Molecular Targets in Non-Small Cell Lung Cancer. 2021; 22(5):.Search in Google Scholar
Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13(10): 5177-5182.QiWXShenZLinFSunYJMinDLTangLNComparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. 2012; 13(10): 5177-5182.Search in Google Scholar
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8(7): 823-859.LindemanNICaglePTBeasleyMBChitaleDADacicSGiacconeGMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013; 8(7): 823-859.Search in Google Scholar
Hanna N, Johnson D, Temin S, Baker S, Brahmer J, Ellis PM, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(30): 3484-3515.HannaNJohnsonDTeminSBakerSBrahmerJEllisPMSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2017; 35(30): 3484-3515.Search in Google Scholar
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic revie w and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5(9): 2892-2911.MidhaADeardenSMcCormackR. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic revie w and global map by ethnicity (mutMapII). 2015; 5(9): 2892-2911.Search in Google Scholar
Lee DH, Srimuninnimit V, Cheng R, Wang X, Orlando M. Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Less ons Learned. Cancer Res Treat. 2015; 47(4): 549-554.LeeDHSrimuninnimitVChengRWangXOrlandoM. Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Less ons Learned. 2015; 47(4): 549-554.Search in Google Scholar
Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. Plos One. 2013; 8(2): e56011.ChoiYLSunJMChoJRampalSHanJParasuramanBEGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. 2013; 8(2): e56011.Search in Google Scholar
Szumera-Cie Kiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, G Ogowski M, Krzakowski M, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 2013; 6(12): 2800-2812.Szumera-Cie KiewiczAOlszewskiWTTysarowskiAKowalskiDMG OgowskiMKrzakowskiMEGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. 2013; 6(12): 2800-2812.Search in Google Scholar
Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. Anticancer Res. 2018; 38(6): 3735-3744.SyrigosKNGeorgouliasVZarogoulidisKMakrantonakisPCharpidouAChristodoulouC. Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. 2018; 38(6): 3735-3744.Search in Google Scholar
Haghgoo SM, Khosravi A, Mortaz E, Pourabdollah-Toutkaboni M, Seifi S, Sabour S, et al. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligan ds in non-small cell lung carcinoma patients. Clin Biochem. 2017; 50(6): 293-300.HaghgooSMKhosraviAMortazEPourabdollah-ToutkaboniMSeifiSSabourSPrognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligan ds in non-small cell lung carcinoma patients. 2017; 50(6): 293-300.Search in Google Scholar
Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, et al. EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A si ngle institution experience. Cancer Epidemiol. 2015; 39(6): 1099-1102.NaderiSGhorraCHaddadFKourieHRRassyMEl KarakFEGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A si ngle institution experience. 2015; 39(6): 1099-1102.Search in Google Scholar
Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013; 8(1): 52-61.YoshizawaASumiyoshiSSonobeMKobayashiMFujimotoMKawakamiFValidation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. 2013; 8(1): 52-61.Search in Google Scholar
Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2): 154-162.ShiYAuJSThongprasertSSrinivasanSTsaiCMKhoaMTA prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). 2014; 9(2): 154-162.Search in Google Scholar
Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015; 10(3): 438-445.YatabeYKerrKMUtomoARajaduraiPTranVKDuXEGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. 2015; 10(3): 438-445.Search in Google Scholar
Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012; 7(2): 323-330.SunPLSeolHLeeHJYooSBKimHXuXHigh incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. 2012; 7(2): 323-330.Search in Google Scholar
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, et al. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017; 114(96-102.TuHYKeEEYangJJSunYLYanHHZhengMYA comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. 2017; 114(96-102.Search in Google Scholar
Jackman DM, Miller VA, Cioffredi LA, Yeap BY, J Nne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untr eated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15(16): 5267-5273.JackmanDMMillerVACioffrediLAYeapBYJ NnePARielyGJImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untr eated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. 2009; 15(16): 5267-5273.Search in Google Scholar
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10): 958-967.RosellRMoranTQueraltCPortaRCardenalFCampsCScreening for epidermal growth factor receptor mutations in lung cancer. 2009; 361(10): 958-967.Search in Google Scholar
Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanism s of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013; 80(3): 235-241.MassarelliEJohnsonFMEricksonHSWistubaIIPapadimitrakopoulouV. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanism s of EGFR tyrosine kinase inhibitors sensitivity and resistance. 2013; 80(3): 235-241.Search in Google Scholar
Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol. 2015; 39(3): 291-297.EstebanEMajemMMartinez AguilloMMartinez BanaclochaNDómineMGómez AldaraviLPrevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. 2015; 39(3): 291-297.Search in Google Scholar
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicent re observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014; 25(1): 126-131.Beau-FallerMPrimNRuppertAMNanni-MetéllusILacaveRLacroixLRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicent re observational study by the French ERMETIC-IFCT network. 2014; 25(1): 126-131.Search in Google Scholar
Lee B, Lee T, Lee SH, Choi YL, Han J. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget. 2016; 7(17): 23874-23884.LeeBLeeTLeeSHChoiYLHanJ. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. 2016; 7(17): 23874-23884.Search in Google Scholar
Calibasi-Kocal G, Amirfallah A, Sever T, Umit Unal O, Gurel D, Oztop I, et al. EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Rep. 2020; 13(2): 2.Calibasi-KocalGAmirfallahASeverTUmit UnalOGurelDOztopIEGFR mutation status in a series of Turkish non-small cell lung cancer patients. 2020; 13(2): 2.Search in Google Scholar
Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. 2013; 109(7): 1821-1828.GahrSStoehrRGeissingerEFickerJHBruecklWMGschwendtnerAEGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. 2013; 109(7): 1821-1828.Search in Google Scholar
Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018; 13(3): 323-358.LindemanNICaglePTAisnerDLArcilaMEBeasleyMBBernickerEHUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018; 13(3): 323-358.Search in Google Scholar